Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and is used to treat HER2-positive metastatic and early breast cancer and metastatic gastric cancer [1–3]. This evidence concerns the gene ERBB2 and breast carcinoma.